Market data and deal flow
Put market figures, pricing and deal activity in context.

A common scale.
Different measures.
US GLP-1 spending across the broader category
Approximately $128 billion in 2025 — analyst calculationAnalyst calculationScope and evidence basis
ASHP reported approximately 14% of $915 billion in total prescription spending. Multiplication gives $128.1 billion; rounded because the underlying share is approximate. ASHP says direct-to-consumer sales are excluded. Includes more than obesity treatment.
US GLP-1 antiobesity medicine spending
$41.6 billion, 2025Reported purchase expenditureScope and evidence basis
Reported pharmaceutical purchase expenditure; not clinic revenue or manufacturer net revenue.
Increase in US net spending attributable to GIP/GLP-1 agonists
$14 billion, 2025 versus 2024Net-spending growth contributionScope and evidence basis
Growth contribution across diabetes and obesity—not total category spending.
Obesity-related component of that net-spending increase
$9.6 billion, 2025 versus 2024Net-spending growth contributionScope and evidence basis
Included within the $14 billion above; do not add the two figures.
Procurement controlled by the target provider cohort
Not establishedNot establishedResearch gap as of November 17, 2026
Scope and evidence basis
Requires provider counts, active patients, access-route mix and evidence of who controls expenditure.
Public evidence supports a large national medicine market, but this research did not identify a defensible market-size series specifically for providers with 10–100 prescribers.
Read the research
What should clinic procurement leaders take away?
The commercial opportunity is substantial, but national medicine spending is not the same as clinic-controlled procurement spend.
Read →What market is this report measuring?
This report separates four commercial layers: | Layer | What belongs in it | How the buyer should use it | |---|---|---| | National medicine market | Pharmaceutical purchases, estimated net spending and manufacturer revenue | Establish scale and direction; do not sum incompatible measures | | Patient access market | Cash-pay offers, insurance cost sharing and manufacturer-linked dispensing | Model affordability and the patient journey | | Clinic-controlled expenditure | Stock purchases where applicable, service contracts, integrations, shipping and internal handling | Identify spending the organization can actually negotiate | | Supporting infrastructure | Pharmacy services, prescription routing, financing, acquisitions and manufacturing investment | Monitor counterparties and potential changes in access arrangements | These are the desk’s analytical categories, not interchangeable accounting measures.
Read →How large is the US GLP-1 market—and what remains unknown?
Public evidence supports a large national medicine market, but this research did not identify a defensible market-size series specifically for providers with 10–100 prescribers.
Read →What do prescription volumes and patient-use data reveal?
There is clear evidence of substantial utilization, but prescriptions, users and active patient-months are different units.
Read →What are the current branded GLP-1 price ranges for clinics to benchmark?
The public prices below are patient-access benchmarks, not wholesale quotes.
Read →How should a clinic turn these prices into a defensible cost model?
Build the model around days supplied and who pays—not the advertised monthly headline.
Read →Which recent deals and activities matter to a clinic buyer?
The most immediately actionable activity is in branded distribution and workflow integration.
Read →9 pages shown
What is still missing from the market evidence?
This report establishes national scale, dated price references and recent activity.
Read →Sources
Sources below were located during this research.
Read →Research quality self-assessment
The research’s own assessment; not an external rating.